Christopher B. Ehrlich, Director at eFFECTOR Therapeutics, Inc. (EFTR), bought 5,000 shares at $5.30 ($27K) on 2022-01-27, disclosed to the SEC on 2022-01-31.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| EFTR | BUY | 2022-02-22 | $13K | — | Filing → |
| EFTR | BUY | 2022-02-10 | $10K | — | Filing → |
| EFTR | BUY | 2022-02-07 | $31K | — | Filing → |